Trials / Completed
CompletedNCT01046136
Mucinex Exploratory Cold Study
Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 378 (actual)
- Sponsor
- Reckitt Benckiser Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | guaifenesin (Mucinex) | bid 7 days |
| DRUG | placebo | bid 7 days |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-03-01
- First posted
- 2010-01-11
- Last updated
- 2020-12-30
- Results posted
- 2012-08-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01046136. Inclusion in this directory is not an endorsement.